Iterum Therapeutics (ITRM) Broadens Patent Estate for Oral Sulopenem

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Iterum Therapeutics (ITRM) Broadens Patent Estate for Oral Sulopenem

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

August 2, 2024 8:00 AM EDT

DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the United States Patent and Trademark Office (USPTO) has issued a notice allowance for two U.S. patents and the Canadian Intellectual Property Office (CIPO) has issued a Canadian patent, all related to sulopenem etzadroxil and probenecid (oral sulopenem).

We are very pleased to... More